Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- Published In:
- The New England journal of medicine, 389(6), 514-526 (2023)
- Authors:
- Jastreboff, Ania M(5), Kaplan, Lee M, Frías, Juan P(2), Wu, Qiwei, Du, Yu, Gurbuz, Sirel, Coskun, Tamer, Haupt, Axel, Milicevic, Zvonko, Hartman, Mark L
- Database ID:
- RPEP-07002
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07002APA
Jastreboff, Ania M; Kaplan, Lee M; Frías, Juan P; Wu, Qiwei; Du, Yu; Gurbuz, Sirel; Coskun, Tamer; Haupt, Axel; Milicevic, Zvonko; Hartman, Mark L. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.. The New England journal of medicine, 389(6), 514-526. https://doi.org/10.1056/NEJMoa2301972
MLA
Jastreboff, Ania M, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.." The New England journal of medicine, 2023. https://doi.org/10.1056/NEJMoa2301972
RethinkPeptides
RethinkPeptides Research Database. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A ..." RPEP-07002. Retrieved from https://rethinkpeptides.com/research/jastreboff-2023-triplehormonereceptor-agonist-retatrutide-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.